Open EyeBeta

A public record of U.S. government and large ownership

Corporate parent

Johnson & Johnson

Johnson & Johnson is a publicly traded healthcare company. Its fiscal 2025 Form 10-K calls it a holding company whose operating companies run two continuing segments, Innovative Medicine and MedTech. It is not a private equity firm. The consumer health business was separated into Kenvue, and Johnson & Johnson owned no Kenvue shares after the fiscal second quarter of 2024. Consumer brands that left with that business are not listed as current products. Many medicines in the key-product list were developed with partners or licensed from other companies.

United States · United States · New Brunswick, New Jersey

Headquarters are New Brunswick, New Jersey. Products are sold in many countries. The United States label is that headquarters.

Firm site

Current records

29 records · page 1 of 2

  • AbiomedMedical devices · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    The fiscal 2025 Form 10-K describes Abiomed as part of the MedTech cardiovascular portfolio. It does not restate a percentage.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • ACUVUEMedical devices · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    The fiscal 2025 Form 10-K says Vision contact lenses are marketed under the ACUVUE brand.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • CAPLYTAPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. The filing says CAPLYTA was acquired with Intra-Cellular Therapies on April 2, 2025.

    As of Apr 2, 2025. Last checked Sep 22, 2026.

  • CARVYKTIPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. The same filing says CARVYKTI is licensed and developed in collaboration with Legend Biotech.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • CONCERTAPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • DARZALEXPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. Janssen Biotech, Inc., described as a wholly owned subsidiary, has an exclusive license from Genmab. Royalties are 12% to 20% of DARZALEX net sales.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • EDURANTPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • ERLEADAPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • IMBRUVICAPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. The filing says IMBRUVICA is developed in collaboration and co-marketed in the United States with Pharmacyclics LLC, an AbbVie company.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • INVEGA SUSTENNAPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • Johnson & Johnson OrthopaedicsMedical devices · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    The fiscal 2025 Form 10-K describes the Orthopaedics portfolio as part of MedTech. In October 2025 the company announced an intention to separate the business, with a targeted completion 18 to 24 months after the announcement. The separation was not completed in this report, so the portfolio is still a current Johnson & Johnson business.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • LAZCLUZEPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • MentorMedical devices · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    The fiscal 2025 Form 10-K says the Surgery portfolio includes breast aesthetics and reconstruction under Mentor.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • OPSUMITPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • PREZISTAPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • REMICADEPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • RYBREVANTPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • ShockwaveMedical devices · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    The fiscal 2025 Form 10-K describes Shockwave as part of the MedTech cardiovascular portfolio. It does not restate a percentage.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • SIMPONIPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

  • SPRAVATOPharmaceuticals · Healthcare
    Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.

Exited or ended

  • KenvuePersonal care · Healthcare
    Johnson & JohnsonControlling stakeHigh confidenceExited

    The fiscal 2025 Form 10-K says Kenvue completed an initial public offering on May 8, 2023, Johnson & Johnson disposed of a further 80.1% on August 23, 2023, and in the fiscal second quarter of 2024 it completed a debt-for-equity exchange of the retained stake. After that exchange the company owned no Kenvue shares. Consumer health results through the exchange offer are discontinued operations.

    Last checked Sep 22, 2026.

How to read these labels